Intra-Individual Changes in Total Procollagen-Type 1 N-terminal Propeptide in a Korean Adult Population

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2022 Oct 27

PMID 36292087

Authors

Rihwa Choi

Sang Gon Lee

Eun Hee Lee

Affiliations

Soon will be listed here.

Abstract

We aimed to investigate intra-individual changes in total procollagen-type 1 N-terminal pro-peptide (P1NP), a biochemical marker of bone turnover, to understand patient populations and test utilization in a Korean adult population while considering different definitions of least significant changes by sex, age, and medical institution type. Overall, 31,501 P1NP tests were performed on 24,644 Korean adults (3389 men and 21,255 women) with a median age of 68.9 years (interquartile range, IQR, 61.2-77.2) for osteoporosis evaluation. Among these, 1331 (5.4%) patients (127 men and 1204 women) underwent ≥3 follow-up P1NP measurements. The median follow-up period was 12.5 months (IQR, 11.7-15.9). Among 1331 patients, 64.4% experienced a decrease in P1NP and 35.6% experienced an increase in P1NP during follow-up. Among these, the proportion of patients who experienced serum P1NP changes ≥14.4% from baseline was 92.3%, and the proportion of patients who achieved ≤40 ng/mL (a median level of premenopausal Korean women) during follow-up was 31.8%. The overall proportion of patients that experienced a serum P1NP change exceeding the least significant change during follow-up was not significantly different by the type of medical institution.

Citing Articles

Correlation between the non-use of cooking oil fume extractors and bone mineral density in population aged 45 years and older in China: a cross-sectional study.

Zhang H, Shi B, Yuan C, Huang C, Huang T, Liao Z Front Endocrinol (Lausanne). 2024; 14:1280429.

PMID: 38239978 PMC: 10794737. DOI: 10.3389/fendo.2023.1280429.

References

Wu C, Chang Y, Chen C, Lewiecki E, Wuster C, Reid I . Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region. J Clin Densitom. 2019; 24(1):3-13. DOI: 10.1016/j.jocd.2019.03.004. View

Eastell R, Szulc P . Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol. 2017; 5(11):908-923. DOI: 10.1016/S2213-8587(17)30184-5. View

Ahn S, Park S, Park S, Yoo J, Jung H, Nho J . Osteoporosis and Osteoporotic Fracture Fact Sheet in Korea. J Bone Metab. 2020; 27(4):281-290. PMC: 7746478. DOI: 10.11005/jbm.2020.27.4.281. View

Ahn S, Park S, Yoo J, Chung Y, Jeon Y, Yoon B . Use of Bone Turnover Markers in Clinical Practice for the Management of Osteoporosis in Korea: From the Survey on the Prescription Pattern of Bone Turnover Markers. J Bone Metab. 2019; 26(4):271-277. PMC: 6901689. DOI: 10.11005/jbm.2019.26.4.271. View

Choi M, Yang J, Seo J, Kim Y, Kang S . Prevalence and diagnosis experience of osteoporosis in postmenopausal women over 50: Focusing on socioeconomic factors. PLoS One. 2021; 16(3):e0248020. PMC: 7924764. DOI: 10.1371/journal.pone.0248020. View

Vasikaran S, Bhattoa H, Eastell R, Heijboer A, Jorgensen N, Makris K . Harmonization of commercial assays for PINP; the way forward. Osteoporos Int. 2020; 31(3):409-412. PMC: 7080559. DOI: 10.1007/s00198-020-05310-6. View

Park S, Ahn S, Yoo J, Chung Y, Jeon Y, Yoon B . Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment. J Bone Metab. 2019; 26(4):213-224. PMC: 6901690. DOI: 10.11005/jbm.2019.26.4.213. View

Yoo J, Park A, Lim Y, Kweon O, Choi J, Do J . Age-related Reference Intervals for Total Collagen-I-N-terminal Propeptide in Healthy Korean Population. J Bone Metab. 2018; 25(4):235-241. PMC: 6288608. DOI: 10.11005/jbm.2018.25.4.235. View

Wang L, Yu W, Yin X, Cui L, Tang S, Jiang N . Prevalence of Osteoporosis and Fracture in China: The China Osteoporosis Prevalence Study. JAMA Netw Open. 2021; 4(8):e2121106. PMC: 8369359. DOI: 10.1001/jamanetworkopen.2021.21106. View

10.

Szulc P, Naylor K, Hoyle N, Eastell R, Leary E . Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability. Osteoporos Int. 2017; 28(9):2541-2556. DOI: 10.1007/s00198-017-4082-4. View

11.

Vasikaran S, Eastell R, Bruyere O, Foldes A, Garnero P, Griesmacher A . Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2010; 22(2):391-420. DOI: 10.1007/s00198-010-1501-1. View

12.

Eastell R, ONeill T, Hofbauer L, Langdahl B, Reid I, Gold D . Postmenopausal osteoporosis. Nat Rev Dis Primers. 2016; 2:16069. DOI: 10.1038/nrdp.2016.69. View

13.

Cavalier E, Eastell R, Jorgensen N, Makris K, Tournis S, Vasikaran S . A multicenter study to evaluate harmonization of assays for N-terminal propeptide of type I procollagen (PINP): a report from the IFCC-IOF Joint Committee for Bone Metabolism. Clin Chem Lab Med. 2019; 57(10):1546-1555. DOI: 10.1515/cclm-2019-0174. View

14.

Park S, Ahn S, Yoo J, Chung Y, Jeon Y, Yoon B . Clinical Application of Bone Turnover Markers in Osteoporosis in Korea. J Bone Metab. 2019; 26(1):19-24. PMC: 6416153. DOI: 10.11005/jbm.2019.26.1.19. View

15.

Diez-Perez A, Naylor K, Abrahamsen B, Agnusdei D, Brandi M, Cooper C . International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int. 2017; 28(3):767-774. PMC: 5302161. DOI: 10.1007/s00198-017-3906-6. View

16.

Watts N, Camacho P, Lewiecki E, Petak S . American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 Update. Endocr Pract. 2021; 27(4):379-380. DOI: 10.1016/j.eprac.2021.02.001. View

17.

Black D, Rosen C . Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med. 2016; 374(3):254-62. DOI: 10.1056/NEJMcp1513724. View

18.

Nishizawa Y, Miura M, Ichimura S, Inaba M, Imanishi Y, Shiraki M . Executive summary of the Japan Osteoporosis Society Guide for the Use of Bone Turnover Markers in the Diagnosis and Treatment of Osteoporosis (2018 Edition). Clin Chim Acta. 2019; 498:101-107. DOI: 10.1016/j.cca.2019.08.012. View

19.

Bhattoa H, Cavalier E, Eastell R, Heijboer A, Jorgensen N, Makris K . Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and β-CTX in blood. Clin Chim Acta. 2020; 515:16-20. PMC: 8033406. DOI: 10.1016/j.cca.2020.12.023. View

20.

Morris H, Eastell R, Jorgensen N, Cavalier E, Vasikaran S, Chubb S . Clinical usefulness of bone turnover marker concentrations in osteoporosis. Clin Chim Acta. 2016; 467:34-41. DOI: 10.1016/j.cca.2016.06.036. View